An E-cadherin positive result on a pathology report is generally considered favorable in oncology, because it means tumor cells have retained a protein that normally keeps cells stuck together and prevents them from wandering off to other parts of the body. E-cadherin acts as a tumor suppressor in most solid cancers, so finding it present usually signals a less aggressive tumor. But “usually” is doing heavy lifting in that sentence, and the real meaning of the result depends on which cancer is being evaluated, what question the pathologist is trying to answer, and where in the disease process the test was ordered.
What E-Cadherin Does in Healthy Tissue
E-cadherin is a protein that sits on the surface of epithelial cells, the cells that line your organs, skin, and glands. Its job is to physically glue neighboring cells together, forming stable junctions that give tissues their shape and structural integrity. These junctions depend on calcium ions to work, which is why the protein’s full name includes “cadherin” (calcium-dependent adhesion).1PubMed Central. Dynamics and functions of E-cadherin complexes in epithelial cell and tissue morphogenesis Beyond just holding cells in place, E-cadherin plays active roles in wound healing and in shaping tissues during development.2PubMed Central. Inside-out regulation of E-cadherin conformation and adhesion
The protein is so fundamental that mouse embryos lacking functional E-cadherin cannot form a basic outer cell layer and die around the time of implantation.3PubMed Central. E-cadherin null mutant embryos fail to form a trophectoderm epithelium Even partial reductions in E-cadherin levels weaken the mechanical stability of cell-to-cell contacts in early embryos.4PubMed Central. Mechanical strengthening of cell-cell adhesion during mouse embryo compaction That gives you a sense of the stakes: without E-cadherin, cells lose the ability to organize into coherent tissues. When cancer researchers talk about E-cadherin loss being a bad sign, this is the underlying reason. A cell that stops expressing this glue protein has, in a sense, lost one of the most basic checks on its behavior.
Why Your Pathologist Ordered the Test
E-cadherin staining is not a routine screening test. It shows up on your pathology report because the pathologist had a specific diagnostic question in mind, and the meaning of a “positive” result changes depending on what that question was.
The most common reason is distinguishing between the two major types of breast cancer. Invasive ductal carcinoma, the more common type, almost always retains strong E-cadherin staining on its cell membranes. Invasive lobular carcinoma, the second most common type, typically loses E-cadherin expression entirely. In one study, all cases of ductal carcinoma showed moderate to strong E-cadherin staining, while only one lobular case showed any meaningful expression.5PubMed Central. E-cadherin expression: a diagnostic utility for differentiating breast carcinomas with ductal and lobular morphologies Another study found normal ductal cells had strong, complete membrane staining in about 85% of ductal carcinoma cases, while all 24 lobular cases showed complete absence of E-cadherin membrane staining.6Diyala Journal of Medicine. The Role of E-cadherin in the Differentiation of Ductal and Lobular Breast Carcinomas So in breast cancer, a positive E-cadherin result often means “this is ductal, not lobular.” That distinction matters for treatment planning, since the two types can behave differently and respond to different therapies.
A less common but equally important use is helping tell the difference between lung adenocarcinoma and pleural mesothelioma, two cancers that can look very similar under the microscope. Lung adenocarcinomas tend to express E-cadherin, while mesotheliomas express a different member of the cadherin family called N-cadherin.7Human Pathology. The differential expression of N-cadherin and E-cadherin distinguishes pleural mesotheliomas from lung adenocarcinomas That said, the reliability of this distinction depends on which specific laboratory antibody is used for the test. One study found that only certain E-cadherin antibody clones clearly separated the two tumor types, while others produced overlap.8PubMed. Value of E-cadherin and N-cadherin immunostaining in the diagnosis of mesothelioma E-cadherin staining alone is not enough to distinguish adenocarcinoma from malignant mesothelioma and is usually combined with other markers.9PubMed. Cytologic differential diagnosis among reactive mesothelial cells, malignant mesothelioma, and adenocarcinoma: utility of combined E-cadherin and calretinin immunostaining
In both of these scenarios, E-cadherin positivity is not telling you whether your cancer is aggressive or mild. It is telling the pathologist what type of cancer you have, which then determines the next steps.
The General Rule for Prognosis
When E-cadherin staining is used to assess aggressiveness rather than type, the general pattern across most solid tumors is straightforward: keeping E-cadherin expression is a better sign than losing it. That is because E-cadherin is classified as a tumor suppressor. When cancer cells lose this protein, they can more easily detach from the primary tumor, invade surrounding tissue, and travel to distant organs, a process broadly called metastasis.10PubMed Central. The functional activity of E-cadherin controls tumor cell metastasis at multiple steps
In stage III colorectal cancer, for example, one study found that negative E-cadherin expression was an independent predictor of worse disease-free survival, with a roughly fivefold increase in the relative risk of recurrence compared to patients whose tumors retained E-cadherin.11Oncology. Loss of E-Cadherin Expression Is Associated with a Poor Prognosis in Stage III Colorectal Cancer The same study found that declining E-cadherin expression was also linked to worse overall survival, though this association did not hold up as strongly after adjusting for other risk factors. The colorectal cancer literature mirrors findings in many other tumor types: losing E-cadherin tracks with more advanced disease, more lymph node involvement, and more distant spread.
Pathologists typically score E-cadherin staining by looking at two things: how much of the cell membrane lights up with the stain, and how intensely. A scoring system used in breast cancer research, for instance, ranges from 0 (completely absent) through grades of weak, moderate, and strong staining, with separate assessments of what percentage of cells show membrane expression.12PubMed Central. E-Cadherin as a diagnostic biomarker in breast cancer So your report might not just say “positive” or “negative” but give a score or a description like “strong membranous staining” versus “weak and heterogeneous.” Stronger, more uniform staining is generally the more reassuring finding.
How Cancer Cells Silence E-Cadherin
The loss of E-cadherin in cancer does not usually happen because the gene is deleted or physically destroyed. More often, the gene is silenced, meaning the cell’s machinery to read and produce the protein gets shut down through chemical modifications. A protein called Snail plays a central role in this process, recruiting a series of enzymes that essentially lock the E-cadherin gene into an “off” position by modifying the surrounding DNA and its packaging proteins.13PubMed Central. Epigenetic regulation of EMT: the Snail story In aggressive breast cancers, this Snail-driven silencing of E-cadherin through DNA modifications contributes to the cancer’s ability to spread.14PubMed Central. Interaction with Suv39H1 is critical for Snail-mediated E-cadherin repression in breast cancer
The reason this matters for your pathology report is that silencing is often reversible. Unlike a permanent gene deletion, a gene that has been chemically switched off can, under the right circumstances, be switched back on. This reversibility is both a reason for optimism in treatment research and a source of complexity when interpreting E-cadherin results at metastatic sites, as we will see shortly.
E-cadherin also intersects with another important cellular pathway involving a protein called beta-catenin. Beta-catenin has two jobs: it helps anchor E-cadherin at the cell surface, and it acts as a signaling molecule that tells cells to grow and divide. When E-cadherin is present and functioning, it sequesters beta-catenin at the cell membrane, keeping it busy with adhesion duties. When E-cadherin is lost, beta-catenin is freed to enter the cell’s nucleus and activate growth-promoting genes.15PubMed. Balancing cell adhesion and Wnt signaling, the key role of beta-catenin So E-cadherin loss has a double effect: cells lose their sticky connections and simultaneously get a push to proliferate.
The Inflammatory Breast Cancer Exception
If the general rule is “E-cadherin positive equals better,” inflammatory breast cancer is the exception that keeps oncologists honest. Inflammatory breast cancer is one of the most aggressive forms of breast cancer, characterized by rapid onset, skin redness and swelling, and extensive invasion of the skin’s lymphatic vessels. And yet, inflammatory breast cancer tumors are almost universally E-cadherin positive. One study found that every single inflammatory breast cancer case expressed E-cadherin, including the tumor cells found within lymphatic vessels, compared to about two-thirds of non-inflammatory breast cancer cases.16PubMed. Persistent E-cadherin expression in inflammatory breast cancer
This finding was initially puzzling. How could a tumor suppressor protein be consistently present in one of the most lethal forms of breast cancer? Research has since shown that in inflammatory breast cancer, E-cadherin actually helps the cancer cells form tight clusters, called tumor emboli, that travel through lymphatic vessels as cohesive groups. These clusters are more efficient at seeding new tumors than individual wandering cells would be. The mechanism involves a modified, clipped version of E-cadherin that promotes a distinctive budding pattern, where parent emboli split off daughter emboli in a geometric fashion, flooding the lymphatic system.17PubMed Central. Geometric tumor embolic budding characterizes inflammatory breast cancer
For patients diagnosed with inflammatory breast cancer, then, a positive E-cadherin result is not reassuring in the way it would be for someone with a different breast cancer subtype. It is a hallmark of the disease itself, and the oncology team will already know to treat it accordingly.
E-Cadherin Can Reappear at Metastatic Sites
Here is where the story gets genuinely complicated. Even in cancers where E-cadherin loss at the primary tumor is a bad prognostic sign, the protein can reappear when cancer cells settle at distant organs. Studies in breast cancer models have shown that a greater percentage of tumor cells expressed E-cadherin at secondary metastatic sites compared to the primary tumor from which they originated.18PubMed Central. E-cadherin re-expression shows in vivo evidence for mesenchymal to epithelial transition in clonal metastatic breast tumor cells The explanation is that metastasis may involve a two-step transition: first, cells at the primary tumor lose their epithelial traits (including E-cadherin) to become mobile, and then, once they arrive at a new organ, they regain epithelial traits to establish themselves and grow.19PubMed Central. Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition
This two-phase model means that E-cadherin positivity in a metastatic deposit does not necessarily mean the cells never went through an aggressive, E-cadherin-negative phase. It may mean they completed the full journey and are now re-expressing the protein to colonize their new location.20PubMed Central. E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas Research over the past decade has increasingly shown that E-cadherin is not simply a brake on cancer spread; it can actively contribute to certain aspects of cancer progression, including collective cell migration.21PubMed Central. Dual role of E-cadherin in cancer cells
For a patient reviewing a biopsy report from a metastatic site, this means an E-cadherin positive result should be interpreted within the full clinical picture, not taken at face value as good news. Your oncologist will weigh it alongside the primary tumor characteristics, the organ involved, and the specific cancer type.
When E-Cadherin Testing Points to a Genetic Syndrome
Occasionally, E-cadherin comes up not because of a current tumor biopsy but because of genetic testing. The gene that codes for E-cadherin is called CDH1, and inherited mutations in CDH1 are the primary cause of hereditary diffuse gastric cancer, a syndrome that carries a high lifetime risk of developing a particularly hard-to-detect form of stomach cancer as well as lobular breast cancer.22PubMed Central. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers Families meeting certain clinical criteria are offered genetic counseling and testing for CDH1 mutations.23PubMed. Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond
Updated clinical guidelines recommend that carriers of pathogenic CDH1 variants consider prophylactic total gastrectomy, the complete removal of the stomach, because diffuse gastric cancer develops beneath the surface lining and is frequently missed by endoscopic surveillance.24PubMed Central. Hereditary diffuse gastric cancer: updated clinical practice guidelines In this context, “E-cadherin” on a report refers to the gene rather than a staining result, and a “positive” finding (meaning a pathogenic mutation was found) is unambiguously concerning, the opposite of what positive staining on a tumor biopsy typically implies. The terminology can be confusing, so if your report involves CDH1 genetic testing, clarifying which kind of “positive” you are dealing with is one of the most important conversations to have with your care team.
Therapeutic Research Targeting E-Cadherin
Because E-cadherin loss is so consistently linked to cancer progression across many tumor types, restoring its expression has become a target for experimental therapies. Several natural compounds have shown the ability to turn E-cadherin back on in laboratory studies of urinary and genital cancers, working by interfering with the signaling pathways that suppress the protein.25PubMed Central. Restoring E-cadherin Expression by Natural Compounds for Anticancer Therapies in Genital and Urinary Cancers More recent research has explored whether re-expressing E-cadherin could also overcome resistance to a cancer-killing signal called TRAIL, which some tumors learn to ignore as they lose their epithelial character.26PubMed. E-cadherin re-expression: Its potential in combating TRAIL resistance and reversing epithelial-to-mesenchymal transition
These approaches are still in early research stages and have not reached routine clinical practice. But they underline the broader significance of your E-cadherin result: it is not just a static snapshot. The protein’s presence or absence reflects a dynamic process that researchers are actively trying to manipulate. If your tumor has lost E-cadherin, future therapies might aim to flip that switch back on.
E-Cadherin Beyond Cancer
E-cadherin testing is overwhelmingly associated with cancer pathology, but the protein matters outside of oncology as well. In the gut, E-cadherin is a key component of the barrier that keeps intestinal contents from leaking through the lining into the body. Defects in this barrier have been implicated in inflammatory bowel disease, and research in animal models has shown that antibodies designed to activate E-cadherin can reduce barrier dysfunction and limit intestinal inflammation.27PubMed Central. E-cadherin activating antibodies limit barrier dysfunction and inflammation in mouse inflammatory bowel disease This research is early and has not translated to approved treatments, but it illustrates that E-cadherin’s role as a tissue organizer has consequences well beyond tumor biology. Any disease where the integrity of an epithelial barrier breaks down, whether in the gut, the kidney, or the lung, could involve E-cadherin dysfunction. For now, though, if E-cadherin appears on your medical report, the question is almost certainly about cancer, and the interpretation follows the principles laid out above.